Seroxo
Seroxo is a world-leading IVD company pioneering a transformative technology called LIT™. This is a patented, 10-minute finger-prick blood test that assesses real-time, 3D neutrophil function. Its applications are in cancer, sepsis, and emergency triage. The LIT™ platform is described as rapid, portable, powerful, and personalized, with potential for AI-driven home testing. The company has a highly experienced and technical team, including founders with significant biotech exit experience. They have clinical data from 8 trials with over 600 patients demonstrating high sensitivity and specificity. Seroxo operates globally and is based in the United Kingdom.
Seroxo
Seroxo is a world-leading IVD company pioneering a transformative technology called LIT™. This is a patented, 10-minute finger-prick blood test that assesses real-time, 3D neutrophil function. Its applications are in cancer, sepsis, and emergency triage. The LIT™ platform is described as rapid, portable, powerful, and personalized, with potential for AI-driven home testing. The company has a highly experienced and technical team, including founders with significant biotech exit experience. They have clinical data from 8 trials with over 600 patients demonstrating high sensitivity and specificity. Seroxo operates globally and is based in the United Kingdom.